Longwood Fund

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events
  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

Sitryx presents new preclinical data highlighting PKM2 as a promising metabolic target for the treatment of atopic dermatitis at the Inflammatory Disease Skin Summit 2025

November 13, 2025

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

November 13, 2025

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 13, 2025

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

November 10, 2025

Inflammation biotech Evommune heads to NYSE with $150M IPO

November 10, 2025

Evommune nabs $150M in IPO amid federal shutdown

November 10, 2025
« Older Entries
Newer Entries »

Longwood Fund

The Prudential Tower

800 Boylston Street
Suite 1715
Boston, MA, 02199

  • About
  • Portfolio
  • Team
  • Press
  • Investor Login
  • Industry Events

© Longwood Fund. All Rights Reserved